Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Abemaciclib (Verzenios) for the treatment of metastatic breastcancer Abemaciclib (Verzenios®) for the treatment of metastatic breastcancer | Report | National Health Care Institute You are here: Abemaciclib (Verzenios®) for the treatment of metastatic breastcancer Search within English part of National Health Care Institute Search Abemaciclib (Verzenios®) for the treatment of metastatic breastcancer Zorginstituut Nederland has completed its assessment of abemaciclib (Verzenios® (...) ) for the treatment of metastatic breastcancer. Due to its expected high costs the Minister of Health, Welfare and Sport (VWS) has placed tisagenlecleucel in the so-called ‘waiting room’ or ‘sluice’ for expensive drugs. These products can only be accepted into the insured package after the Zorginstituut has advised on their inclusion in the insured package and, where applicable, subject to Ministry negotiations to arrive at a financial arrangement with the supplier. The Zorginstituut was advised by two
Strategies to Identify Women at High Risk of Advanced BreastCancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breastcancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breastcancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breastcancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at BreastCancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data
Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After BreastCancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breastcancer surgery. Although there is insufficient evidence to support any preventative strategy, prior literature suggests the possible efficacy (...) of intravenous lidocaine and perioperative pregabalin in preventing persistent pain after surgery. To determine feasibility of conducting a larger definitive trial, we conducted a multicenter 2 × 2 factorial, randomized, placebo-controlled pilot trial of 100 female patients undergoing breastcancer surgery. Patients were randomized to receive an intraoperative lidocaine infusion (1.5 mg/kg bolus followed by 2 mg/kg/h) or placebo and perioperative pregabalin (300 mg preoperatively, 75 mg twice daily for 9
Resection of Cavity Shave Margins in Stage 0-III BreastCancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial Single-center studies have demonstrated that resection of cavity shave margins (CSM) halves the rate of positive margins and re-excision in breastcancer patients undergoing partial mastectomy (PM). We sought to determine if these findings were externally generalizable across practice settings.In this multicenter randomized (...) controlled trial occurring in 9 centers across the United States, stage 0-III breastcancer patients undergoing PM were randomly assigned to either have resection of CSM ("shave" group) or not ("no shave" group). Randomization occurred intraoperatively, after the surgeon had completed their standard PM. Primary outcome measures were positive margin and re-excision rates.Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial. Four patients (2 in each arm) did not meet inclusion
Methods for Development of the European Commission Initiative on BreastCancer Guidelines: Recommendations in the Era of Guideline Transparency. Neither breastcancer prevention and early-detection programs, nor their outcomes, are uniform across Europe. This article describes the rationale, methods, and process for development of the European Commission (EC) Initiative on BreastCancer Screening and Diagnosis Guidelines. To be consistent with standards set by the Institute of Medicine
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With BreastCancer Trastuzumab is highly effective for human epidermal growth factor receptor type 2 (HER2)-positive breastcancer but is associated with a decline in left ventricular ejection fraction.The purpose of this study was to determine whether angiotensin-converting enzyme inhibitors or beta-blockers reduce the rate of trastuzumab-induced cardiotoxicity (left ventricular ejection fraction (...) decrease >10%, or >5% if below 50%) and limit treatment interruptions.In this double-blind, multicenter, placebo-controlled trial, cardiotoxicity and treatment interruptions in patients with HER2-positive breastcancer treated with trastuzumab for 12 months were evaluated over a 2-year period. Patients were stratified by anthracycline use and then randomized to receive lisinopril, carvedilol, or placebo.The study included 468 women, age 51 ± 10.7 years. For the entire cohort, cardiotoxicity
Alpelisib (Piqray) - Breastcancer Drug Approval Package: Piqray U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Piqray Company: Novartis Pharmaceuticals Corporation Application Number: 212526 Approval Date: 05/24/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created
Can a brief psychological expectancy intervention improve postoperative pain? A randomized, controlled trial in patients with breastcancer Pain after surgery remains a major health problem, calling for optimized treatment regimens to maximize the efficacy of pharmacological interventions. In this randomized controlled trial, we tested in a routine surgical treatment setting whether postoperative pain can be reduced by a brief preoperative intervention, ie, positive verbal suggestions (...) in combination with sham acupuncture, designed to optimize treatment expectations. We hypothesized that the expectancy intervention as add-on to patient-controlled intravenous analgesia with morphine reduces patient-reported postoperative pain and improves satisfaction with analgesia. Ninety-six women undergoing breastcancer surgery were randomized at 2 stages: Before surgery, anesthesiologists delivered either positive or neutral verbal suggestions regarding the benefits of acupuncture needling
Seaweed Consumption and Its Effect on BreastCancer "Seaweed Consumption and Its Effect on BreastCancer" by Alyssa MouaLee and Thanita Pradhanang < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Breastcancer remains the most common cancer in women worldwide. Interestingly, breastcancer incidence varies dramatically among countries. Japan, in particular, has (...) relatively low breastcancer (BC) rates when compared to those in Western countries. Daily consumption of seaweed has been proposed as one of the factors in explaining the difference in incidence rates of BC. The high concentrations of polysaccharides in seaweed have been reported in many studies to have anti-cancer effects as well as chemoprotective effects. The aim for this review is to look at the potential benefits of seaweed consumption and its effect on breastcancer. Methods: Exhaustive search
NAB-Paclitaxel Improves Disease-Free Survival in Early BreastCancer: GBG 69-GeparSepto The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate compared with weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breastcancer (BC). Here, we report data on long-term outcomes.Patients with histologically confirmed primary BC
MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of BreastCancer MRI performance in detecting pathologic complete response (pCR) post-neoadjuvant chemotherapy (NAC) in breastcancer has been previously explored. However, since tumor response varies by molecular subtype, it is plausible that imaging performance also varies. Therefore, we performed a literature review on subtype-specific MRI performance in detecting pCR post-NAC.Two reviewers searched Cochrane (...) , PubMed, and EMBASE for articles published between 2013 and 2018 that examined MRI performance in detecting pCR post-NAC. After filtering, ten primary research articles were included. Statistical metrics, such as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were extracted per study for triple negative, HR+/HER2-, and HER2+ patients.Ten studies involving 2310 patients were included. In triple negative breastcancer, MRI showed NPV (58-100%) and PPV
Palbociclib (Ibrance) - hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breastcancer 1 Published 8 July 2019 1 SMC2149 palbociclib 75mg, 100mg, and 125mg hard capsules (Ibrance®) Pfizer Limited 7 June 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission considered under the end of life and orphan equivalent assessment process. palbociclib (Ibrance ® ) is accepted for use within NHSScotland. Indication under review: for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breastcancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre
Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early BreastCancer: SenSzi (GBG80) Trial The aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB).In a prospective, multicenter, randomized phase III trial, patients with cN0 early breastcancer or extensive/high-grade ductal carcinoma in situ planned for standard (...) and Swiss breast centers. Modified intention-to-treat analysis (n = 1,163) showed a mean number of histologically detected SLNs of 2.21 with LSG and 2.26 without LSG (difference 0.05; stratified 95% CI, -0.18 to infinity), thus establishing noninferiority of omitting preoperative LSG. Secondary end points displayed no statistically significant differences.We show that SLNB is equally effective irrespective of the surgeon's knowledge of preoperative LSG results. SLNB without LSG will speed up
Two-view digital breast tomosynthesis versus digital mammography in a population-based breastcancer screening programme (To-Be): a randomised, controlled trial Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening (...) cancer, stratified by screening technique (ie, digital breast tomosynthesis and digital mammography). A log-binomial regression model was used to estimate the efficacy of digital breast tomosynthesis versus digital mammography, defined as the crude risk ratios (RRs) with 95% CIs for screen-detected breastcancer for women screened during the recruitment period. A per-protocol approach was used in the analyses. This trial is registered at ClinicalTrials.gov, number NCT02835625, and is closed
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breastcancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breastcancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non (...) -inferior to the standard 12-month treatment regarding disease-free survival.This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly assigned patients with HER2-positive early breastcancer, aged 18 years or older, and with a clear indication for chemotherapy, by a computerised minimisation process (1:1), to receive either 6-month or 12-month trastuzumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed
2019LancetControlled trial quality: predicted high
6 months versus 12 months of adjuvant trastuzumab in early breastcancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned final analysis based on the prespecified number of occurring events.PHARE is an open-label, phase 3, non-inferiority (...) randomised trial of patients with HER2-positive early breastcancer comparing 6 months versus 12 months of trastuzumab treatment concomitant with or following standard neoadjuvant or adjuvant chemotherapy. The study was undertaken in 156 centres in France. Eligible patients were women aged 18 years or older with non-metastatic, operable, histologically confirmed adenocarcinoma of the breast and either positive axillary nodes or negative axillary nodes but a tumour of at least 10 mm. Participants must
2019LancetControlled trial quality: predicted high
Investigating causal relations between sleep traits and risk of breastcancer in women: mendelian randomisation study. To examine whether sleep traits have a causal effect on risk of breast cancer.Mendelian randomisation study.UK Biobank prospective cohort study and BreastCancer Association Consortium (BCAC) case-control genome-wide association study.156 848 women in the multivariable regression and one sample mendelian randomisation (MR) analysis in UK Biobank (7784 with a breastcancer (...) diagnosis) and 122 977 breastcancer cases and 105 974 controls from BCAC in the two sample MR analysis.Self reported chronotype (morning or evening preference), insomnia symptoms, and sleep duration in multivariable regression, and genetic variants robustly associated with these sleep traits.Breast cancer diagnosis.In multivariable regression analysis using UK Biobank data on breastcancer incidence, morning preference was inversely associated with breastcancer (hazard ratio 0.95, 95% confidence
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for BreastCancer. The use of adjuvant chemotherapy in patients with breastcancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breastcancer recurrence adds prognostic information to the recurrence score is not known.We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal (...) growth factor receptor 2-negative, axillary node-negative breastcancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breastcancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50